Subject:
- Active Substance: Polatuzumab vedotin
- Name: Polivy
- Therapeutic area: Diffuse large B-cell lymphoma (DLBCL)
- Pharmaceutical company: Roche Pharma AG
Time table:
- Publication of project plan: 22.11.2019
- Publication of final assessment expected: 13.02.2020
Assessment information:
- Title: Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
- Author/Co-Author: IQWiG (Germany), HAS (France)
- Dedicated Reviewers: FIMEA (Finland), SUKL (Czech Republic), TLV (Sweden), INFARMED (Portugal)
- Observer: GBA (Germany)
› G-BA assessment available (D-507)